Literature DB >> 22837101

In vivo infection by Trypanosoma cruzi: a morphometric study of tissue changes in mice.

Viviane Rodrigues Esperandim1, Daniele da Silva Ferreira, Karen Cristina Sousa Rezende, Wilson Roberto Cunha, Juliana Saraiva, Jairo Kenupp Bastos, Márcio Luis Andrade E Silva, Sérgio de Albuquerque.   

Abstract

Nifurtimox and benznidazole, medications currently used for the treatment of the Chagas disease, are not always successful. We determine whether (-)-cubebin and (-)-hinokinin could be used as alternative drugs for the treatment of parasitic infections by Trypanosoma cruzi. To this end, male BALB/c mice were treated with both drugs, and the nuclear parameters (largest diameter, smallest diameter, and perimeter) were determined from slides prepared from the spleen, liver, and heart. The cytotoxicity of the substances was determined after 24-h treatment. Results revealed increased cell nuclei in untreated infected animals as compared to uninfected mice. The values obtained for infected animals treated with (-)-cubebin and (-)-hinokinin were close to those observed for uninfected mice. For the spleen, perimeter values of 10.85 μm (p < 0.01) and 10.90 μm (p < 0.05) were obtained for mice treated with (-)-cubebin 50 mg/kg and (-)-hinokinin 20 mg/kg, respectively, whereas untreated infected animals furnished a perimeter of 11.76 μm. As for the liver, perimeter values of 19.06 μm (p < 0.01) and 18.61 μm (p < 0.001) were achieved for mice treated with (-)-cubebin 50 mg/kg and (-)-hinokinin 20 mg/kg, respectively, whereas a perimeter of 18.54 μm was obtained for untreated infected animals. The cytotoxicity assays demonstrated that (-)-cubebin and (-)-hinokinin does not display toxicity. Therefore, (-)-cubebin and (-)-hinokinin are promising therapeutic agents and could be used in future clinical studies concerning treatment of the Chagas disease. Even if the karyometry is not used frequently, it can complement other methods, such as PCR, and furthermore, it is a simple method which is easily possible to analyze the activity of substances in the tissues of treated infected animals compared to uninfected animals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22837101     DOI: 10.1007/s00436-012-3048-x

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  19 in total

1.  Update on Chagas heart disease on the first centenary of its discovery.

Authors:  Jose A Marin-Neto; Anis Rassi
Journal:  Rev Esp Cardiol       Date:  2009-11       Impact factor: 4.753

Review 2.  Natural products and Chagas' disease: a review of plant compounds studied for activity against Trypanosoma cruzi.

Authors:  Erika Izumi; Tânia Ueda-Nakamura; Benedito Prado Dias Filho; Valdir Florêncio Veiga Júnior; Celso Vataru Nakamura
Journal:  Nat Prod Rep       Date:  2011-02-03       Impact factor: 13.423

3.  Reduction of parasitism tissue by treatment of mice chronically infected with Trypanosoma cruzi with lignano lactones.

Authors:  Viviane Rodrigues Esperandim; Daniele da Silva Ferreira; Juliana Saraiva; Márcio Luis Andrade Silva; Eveline Soares Costa; Ana Carolina Pereira; Jairo Kenupp Bastos; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2010-05-04       Impact factor: 2.289

4.  In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi.

Authors:  Juliana Saraiva; Celeste Vega; Mirian Rolon; Rosangela da Silva; Márcio Luis Andrade E Silva; Paulo Marcos Donate; Jairo Kenupp Bastos; Alícia Gomez-Barrio; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2006-10-12       Impact factor: 2.289

Review 5.  Immunopathology of cardiomyopathy in the experimental Chagas disease.

Authors:  M B Soares; R R Santos
Journal:  Mem Inst Oswaldo Cruz       Date:  1999       Impact factor: 2.743

6.  Evaluation of the trypanocidal activity of lignans isolated from the leaves of Zanthoxylum naranjillo.

Authors:  J K Bastos; S Albuquerque; M L Silva
Journal:  Planta Med       Date:  1999-08       Impact factor: 3.352

7.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.

Authors:  F S Buckner; C L Verlinde; A C La Flamme; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition.

Authors:  Tepy Usia; Tadashi Watabe; Shigetoshi Kadota; Yasuhiro Tezuka
Journal:  Life Sci       Date:  2005-04-01       Impact factor: 5.037

9.  Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery.

Authors:  José Rodrigues Coura; João Carlos Pinto Dias
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

Review 10.  Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease).

Authors:  Herbert B Tanowitz; Fabiana S Machado; Linda A Jelicks; Jamshid Shirani; Antonio C Campos de Carvalho; David C Spray; Stephen M Factor; Louis V Kirchhoff; Louis M Weiss
Journal:  Prog Cardiovasc Dis       Date:  2009 May-Jun       Impact factor: 8.194

View more
  1 in total

1.  Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.

Authors:  Rômulo Dias Novaes; Eliziária C Santos; Marli C Cupertino; Daniel S S Bastos; Jerusa M Oliveira; Thaís V Carvalho; Mariana M Neves; Leandro L Oliveira; André Talvani
Journal:  Parasitol Res       Date:  2015-04-28       Impact factor: 2.289

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.